Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from CellaVision AB ( (SE:CEVI) ).
CellaVision has announced the formation of its Nomination Committee ahead of the 2026 Annual General Meeting, scheduled for April 28 in Lund. The committee, chaired by Joel Eklund, will propose candidates for key positions such as the Chairman of the General Meeting and members of the Board of Directors. This announcement is a routine part of CellaVision’s governance process, ensuring structured leadership and strategic planning for the company’s future operations.
The most recent analyst rating on (SE:CEVI) stock is a Buy with a SEK199.00 price target. To see the full list of analyst forecasts on CellaVision AB stock, see the SE:CEVI Stock Forecast page.
More about CellaVision AB
CellaVision is a global medical technology company specializing in developing and selling advanced systems for routine blood and body fluid analysis in healthcare services. Their products, which replace manual laboratory work, are crucial for accurate disease diagnosis, particularly for infections and serious cancers. The company leverages expertise in sample preparation, image analysis, AI, and automated microscopy, and operates through global partners and local market support organizations across more than 40 countries. CellaVision is headquartered in Lund, Sweden, and its shares are listed on the Nasdaq Stockholm, Mid Cap list.
Average Trading Volume: 22,380
Technical Sentiment Signal: Sell
Current Market Cap: SEK4.35B
For a thorough assessment of CEVI stock, go to TipRanks’ Stock Analysis page.